Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

325 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Increasing Annual Cancer Incidence in Patients Age 20-49 Years: A Real-Data Study.
Ribelles N, Pascual J, Galvez-Carvajal L, Ruiz-Medina S, Garcia-Corbacho J, Benitez JC, Dominguez-Recio ME, Torres E, Oliva L, Zalabardo M, Rueda A, Alba E. Ribelles N, et al. Among authors: alba e. JCO Glob Oncol. 2024 Mar;10:e2300363. doi: 10.1200/GO.23.00363. JCO Glob Oncol. 2024. PMID: 38513186 Free PMC article.
Significant Decrease in Annual Cancer Diagnoses in Spain during the COVID-19 Pandemic: A Real-Data Study.
Ruiz-Medina S, Gil S, Jimenez B, Rodriguez-Brazzarola P, Diaz-Redondo T, Cazorla M, Muñoz-Ayllon M, Ramos I, Reyna C, Bermejo MJ, Godoy A, Torres E, Cobo M, Galvez L, Rueda A, Alba E, Ribelles N. Ruiz-Medina S, et al. Among authors: alba e. Cancers (Basel). 2021 Jun 28;13(13):3215. doi: 10.3390/cancers13133215. Cancers (Basel). 2021. PMID: 34203185 Free PMC article.
Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HR+)/HER2-negative advanced breast cancer patients.
Ribelles N, Jerez JM, Rodriguez-Brazzarola P, Jimenez B, Diaz-Redondo T, Mesa H, Marquez A, Sanchez-Muñoz A, Pajares B, Carabantes F, Bermejo MJ, Villar E, Dominguez-Recio ME, Saez E, Galvez L, Godoy A, Franco L, Ruiz-Medina S, Lopez I, Alba E. Ribelles N, et al. Among authors: alba e. Eur J Cancer. 2021 Feb;144:224-231. doi: 10.1016/j.ejca.2020.11.030. Epub 2020 Dec 26. Eur J Cancer. 2021. PMID: 33373867
Targeted treatment approaches in refractory germ cell tumors.
Galvez-Carvajal L, Sanchez-Muñoz A, Ribelles N, Saez M, Baena J, Ruiz S, Ithurbisquy C, Alba E. Galvez-Carvajal L, et al. Among authors: alba e. Crit Rev Oncol Hematol. 2019 Nov;143:130-138. doi: 10.1016/j.critrevonc.2019.09.005. Epub 2019 Sep 25. Crit Rev Oncol Hematol. 2019. PMID: 31634730 Free article. Review.
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.
Díaz-Redondo T, Lavado-Valenzuela R, Jimenez B, Pascual T, Gálvez F, Falcón A, Alamo MDC, Morales C, Amerigo M, Pascual J, Sanchez-Muñoz A, González-Guerrero M, Vicioso L, Laborda A, Ortega MV, Perez L, Fernandez-Martinez A, Chic N, Jerez JM, Alvarez M, Prat A, Ribelles N, Alba E. Díaz-Redondo T, et al. Among authors: alba e. Front Oncol. 2019 Nov 5;9:1178. doi: 10.3389/fonc.2019.01178. eCollection 2019. Front Oncol. 2019. PMID: 31750258 Free PMC article.
325 results